Malaria Vaccine Safe, Immunogenic and Efficacious in Young Infants
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Malaria Vaccine Safe, Immunogenic and Efficacious in Young Infants

LONDON, U.K. -- October 26, 2007 -- Initial findings from studies to test a malaria vaccine in African infants are promising, conclude authors of an article published early Online and in an upcoming edition of The Lancet.

Dr. Pedro Alonso, Manhica Health Research Centre, Mozambique, and Hospital Clinic of the Universitat de Barcelona, Spain, and colleagues, did a double-blind trial of 214 infants in Mozambique to test the safety, immunogenicity, and efficacy of the malaria vaccine RTS,S/ AS02D.

Children were randomly assigned to received three doses of the vaccine or hepatitis B vaccine Energix-B (as a control) at ages 10 weeks, 14 weeks and 18 weeks, as well as routine immunisation vaccines given at eight, 12, and 16 weeks of age.

They found that the vaccine was safe (the primary purpose of the trial), since there were no vaccine-related serious adverse events in either the vaccine or control groups, nor an imbalance in unsolicited adverse events between the two groups. Further, they found that for children vaccinated the risk of contracting new malaria infections reduced by 65% -- compared with a previous efficacy of 45% reported in a trial of children aged one to four years.

The authors point out that all study participants were provided with free-insecticide treated bednets and their homes were sprayed with insecticide twice.

They say: "The trial was undertaken in an area of high transmission, but in the context of renewed and intense malaria control activities...the future use and deployment of a malaria vaccine should be seen in the context of comprehensive malaria control programmes."

They conclude that the study provides evidence of a strong association between vaccine induced antibodies and reduction of risk of malaria infection. They say: "This is of great significance because up until now, immunogenicity was a marker of response with no clearly proven relation to protection, which in turn could only be established with a clinical trial. This finding needs to be corroborated further in other trials, but this observation might be important in the clinical development plan of this vaccine."

SOURCE: The Lancet

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities